---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-082999"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:10:16.280987+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "medium"
source: SEC EDGAR
---

# VYNE CSO presents InhiBET platform at B&T Cell-Mediated Autoimmune Conference

## Summary
- CSO Iain Stuart, Ph.D., presented at B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022.
- Presentation covered the InhiBET platform for bromodomain & end terminal (BET) inhibitors in autoimmune disease.
- No new clinical data, financial results, or guidance changes disclosed in the filing or presentation exhibit.

## SEC filing metadata
- accession: 0001104659-22-082999
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922082999/0001104659-22-082999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922082999/tm2221840d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-082999
- JSON: https://secwatch.observer/filing/0001104659-22-082999.json
- Plain text: https://secwatch.observer/filing/0001104659-22-082999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.